All Articles

Joining an LNN is a great way to connect with other navigators while enhancing your ability to improve outcomes and the survivorship experience for patients. Here’s how.

Local Navigator Networks are enhancing the professional growth of navigators – here’s what you should know about this fresh approach to networking!

Leaders of the AONN+ Local Navigator Networks share lessons in implementing and sustaining their programs.

Experts reveal the key components to building and sustaining effective Local Navigator Networks.

Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients.

US Food and Drug Administration–approved capmatinib is an effective second-line treatment for patients with MET exon 14–mutated NSCLC.

First-line treatment with ramucirumab plus erlotinib in patients with EGFR-mutated metastatic NSCLC was associated with superior progression-free survival compared with erlotinib plus placebo.

Lorlatinib is associated with longer progression-free survival and a higher overall and intracranial response rates among patients with previously untreated, advanced ALK-positive NSCLC.

Selpercatinib and pralsetinib are US Food and Drug Administration–approved treatment options for patients with RET fusion–positive NSCLC.